-
Press ReleaseNovartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
-
Press ReleaseNovartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
-
Press ReleaseNovartis announces plans to build flagship manufacturing hub in North Carolina
-
Press ReleaseNovartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
-
Press ReleaseNovartis completes acquisition of Tourmaline Bio
-
Press ReleaseNovartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt
-
Press ReleaseNovartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
-
Press ReleaseNovartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
-
Press ReleaseNovartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
-
Press ReleaseNovartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
-
Press ReleaseNovartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
-
Press ReleaseNovartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025